HRH3 and relapsing-remitting multiple sclerosis: In a recent Phase II, randomized, placebo-controlled study of 131 patients with relapsing-remitting MS over 48 weeks of treatment, treatment with the H3R inverse agonist GSK239512 was shown to produce a small but positive effect on remyelination.